{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:13:59Z","timestamp":1793664839683,"version":"4.5.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T00:00:00Z","timestamp":1696291200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1053\/j.ajkd.2023.08.010","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T21:23:42Z","timestamp":1695936222000},"page":"340-349.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Ofatumumab in Rituximab-Resistant and Rituximab-Intolerant Patients With Primary Membranous Nephropathy: A Case Series"],"prefix":"10.1053","volume":"83","author":[{"given":"Manuel Alfredo","family":"Podest\u00e0","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matias","family":"Trillini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Portalupi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Gennarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Tomatis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Perna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Rubis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Remuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero","family":"Ruggenenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1053\/j.ajkd.2023.08.010_bib1","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrneph.2017.92","article-title":"Treatment of membranous nephropathy: time for a paradigm shift","volume":"13","author":"Ruggenenti","year":"2017","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2023.08.010_bib2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1056\/NEJM199307083290203","article-title":"Prognosis of untreated patients with idiopathic membranous nephropathy","volume":"329","author":"Schieppati","year":"1993","journal-title":"N\u00a0Engl J Med"},{"issue":"9337","key":"10.1053\/j.ajkd.2023.08.010_bib3","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0140-6736(02)11042-7","article-title":"Rituximab for idiopathic membranous nephropathy","volume":"360","author":"Remuzzi","year":"2002","journal-title":"Lancet"},{"issue":"1","key":"10.1053\/j.ajkd.2023.08.010_bib4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1053\/j.ajkd.2023.08.010_bib5","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1681\/ASN.2020071082","article-title":"New \u201cantigens\u201d in membranous nephropathy","volume":"32","author":"Sethi","year":"2021","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"10","key":"10.1053\/j.ajkd.2023.08.010_bib6","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1681\/ASN.2014070640","article-title":"Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy","volume":"26","author":"Ruggenenti","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2023.08.010_bib7","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1053\/j.ajkd.2023.08.010_bib8","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1681\/ASN.2016040449","article-title":"Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up","volume":"28","author":"Dahan","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2023.08.010_bib9","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1681\/ASN.2020071091","article-title":"Rituximab or cyclophosphamide in the treatment of membranous nephropathy: the RI-CYCLO randomized trial","volume":"32","author":"Scolari","year":"2021","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"9","key":"10.1053\/j.ajkd.2023.08.010_bib10","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1681\/ASN.2016091022","article-title":"Safety of rituximab compared with steroids and cyclophosphamide for idiopathic membranous nephropathy","volume":"28","author":"van den Brand","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2023.08.010_bib11","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ajkd.2023.08.010_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-021-00303-z","article-title":"Membranous nephropathy","volume":"7","author":"Ronco","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"10.1053\/j.ajkd.2023.08.010_bib13","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.2215\/CJN.01730408","article-title":"Effects of rituximab on morphofunctional abnormalities of membranous glomerulopathy","volume":"3","author":"Ruggenenti","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"10.1053\/j.ajkd.2023.08.010_bib14","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1681\/ASN.2012020181","article-title":"Rituximab in idiopathic membranous nephropathy","volume":"23","author":"Ruggenenti","year":"2012","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2023.08.010_bib15","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.3389\/fimmu.2019.03069","article-title":"Neutralizing anti-rituximab antibodies and relapse in membranous nephropathy treated with rituximab","volume":"10","author":"Boyer-Suavet","year":"2019","journal-title":"Front Immunol"},{"issue":"1","key":"10.1053\/j.ajkd.2023.08.010_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2019-232896","article-title":"Ofatumumab for multirelapsing membranous nephropathy complicated by rituximab-induced serum-sickness","volume":"13","author":"Podest\u00e0","year":"2020","journal-title":"BMJ Case Rep"},{"issue":"8","key":"10.1053\/j.ajkd.2023.08.010_bib17","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.2165\/11203850-000000000-00000","article-title":"Ofatumumab","volume":"70","author":"Sanford","year":"2010","journal-title":"Drugs"},{"issue":"5","key":"10.1053\/j.ajkd.2023.08.010_bib18","doi-asserted-by":"crossref","first-page":"932","DOI":"10.2215\/CJN.01180307","article-title":"Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy","volume":"2","author":"Cravedi","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2023.08.010_bib19","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1681\/ASN.V62257","article-title":"Plasma clearance of nonradioactive iohexol as a measure of glomerular filtration rate","volume":"6","author":"Gaspari","year":"1995","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2023.08.010_bib20","first-page":"899","article-title":"Definition of a new cut-off for the anti-phospholipase A2 receptor (PLA2R) autoantibody immunoassay in patients affected by idiopathic membranous nephropathy","volume":"31","author":"Tampoia","year":"2018","journal-title":"J\u00a0Nephrol"},{"key":"10.1053\/j.ajkd.2023.08.010_bib21","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.cca.2013.03.015","article-title":"Development of a standardized ELISA for the determination of autoantibodies against human M-type phospholipase A2 receptor in primary membranous nephropathy","volume":"421","author":"D\u00e4hnrich","year":"2013","journal-title":"Clin Chim Acta"},{"key":"10.1053\/j.ajkd.2023.08.010_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.958136","article-title":"Sexual dimorphic response to rituximab treatment: a longitudinal observational study in a large cohort of patients with primary membranous nephropathy and persistent nephrotic syndrome","volume":"13","author":"Perna","year":"2022","journal-title":"Front Pharmacol"},{"issue":"12","key":"10.1053\/j.ajkd.2023.08.010_bib23","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.2215\/CJN.05080610","article-title":"Rituximab therapy in idiopathic membranous nephropathy: a 2-year study","volume":"5","author":"Fervenza","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"10.1053\/j.ajkd.2023.08.010_bib24","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.2217\/fon.14.73","article-title":"Ofatumumab as front-line therapy in untreated chronic lymphocytic leukemia","volume":"10","author":"Reagan","year":"2014","journal-title":"Future Oncol"},{"key":"10.1053\/j.ajkd.2023.08.010_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.572863","article-title":"Rituximab hypersensitivity: from clinical presentation to management","volume":"11","author":"Fouda","year":"2020","journal-title":"Front Pharmacol"},{"issue":"12","key":"10.1053\/j.ajkd.2023.08.010_bib26","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1136\/ard.2011.151522","article-title":"Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial","volume":"70","author":"Taylor","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1053\/j.ajkd.2023.08.010_bib27","doi-asserted-by":"crossref","first-page":"362","DOI":"10.4049\/jimmunol.177.1.362","article-title":"The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20","volume":"177","author":"Teeling","year":"2006","journal-title":"J\u00a0Immunol"},{"issue":"6505","key":"10.1053\/j.ajkd.2023.08.010_bib28","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1126\/science.abb8008","article-title":"Binding mechanisms of therapeutic antibodies to human CD20","volume":"369","author":"Kumar","year":"2020","journal-title":"Science"},{"issue":"1","key":"10.1053\/j.ajkd.2023.08.010_bib29","doi-asserted-by":"crossref","first-page":"749","DOI":"10.4049\/jimmunol.0900632","article-title":"Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX","volume":"183","author":"Pawluczkowycz","year":"2009","journal-title":"J\u00a0Immunol"},{"issue":"6","key":"10.1053\/j.ajkd.2023.08.010_bib30","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1182\/blood-2004-01-0039","article-title":"Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas","volume":"104","author":"Teeling","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.ajkd.2023.08.010_bib31","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.3389\/fimmu.2019.01340","article-title":"Imaging mass cytometry and single-cell genomics reveal differential depletion and repletion of B-cell populations following ofatumumab treatment in cynomolgus monkeys","volume":"10","author":"Theil","year":"2019","journal-title":"Front Immunol"},{"issue":"6","key":"10.1053\/j.ajkd.2023.08.010_bib32","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1111\/ajt.12220","article-title":"A\u00a0single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function","volume":"13","author":"Kamburova","year":"2013","journal-title":"Am J Transplant"},{"issue":"2","key":"10.1053\/j.ajkd.2023.08.010_bib33","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/j.1600-6143.2006.01632.x","article-title":"The effect of desensitization protocols on human splenic B-cell populations in\u00a0vivo","volume":"7","author":"Ramos","year":"2007","journal-title":"Am J Transplant"},{"issue":"6","key":"10.1053\/j.ajkd.2023.08.010_bib34","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1093\/rheumatology\/key428","article-title":"Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis","volume":"58","author":"Ramwadhdoebe","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1053\/j.ajkd.2023.08.010_bib35","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.ekir.2020.06.030","article-title":"Obinutuzumab is effective for the treatment of refractory membranous nephropathy","volume":"5","author":"Sethi","year":"2020","journal-title":"Kidney Int Rep"},{"issue":"6","key":"10.1053\/j.ajkd.2023.08.010_bib36","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1053\/j.ajkd.2020.02.444","article-title":"Successful treatment of patients with refractory PLA2R-associated membranous nephropathy with obinutuzumab: a report of 3 cases","volume":"76","author":"Klomjit","year":"2020","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"10.1053\/j.ajkd.2023.08.010_bib37","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/blood-2014-02-555169","article-title":"A\u00a0unique population of IgG-expressing plasma cells lacking CD19 is enriched in human bone marrow","volume":"125","author":"Mei","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.ajkd.2023.08.010_bib38","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1159\/000516984","article-title":"Membranous nephropathy: it is time to go back to the future","volume":"145","author":"Sabiu","year":"2021","journal-title":"Nephron"},{"issue":"3","key":"10.1053\/j.ajkd.2023.08.010_bib39","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.kint.2021.12.019","article-title":"Daratumumab for multidrug-resistant phospholipase-A2 receptor-related membranous nephropathy","volume":"101","author":"Vink","year":"2022","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.ajkd.2023.08.010_bib40","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.kint.2021.11.001","article-title":"Anti-CD38 therapy for PLA2R-positive membranous nephropathy resistant to conventional immunosuppression","volume":"101","author":"Stehl\u00e9","year":"2022","journal-title":"Kidney Int"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638623008387?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638623008387?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T03:50:24Z","timestamp":1759463424000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638623008387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0272638623008387"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2023.08.010","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ofatumumab in Rituximab-Resistant and Rituximab-Intolerant Patients With Primary Membranous Nephropathy: A Case Series","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2023.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}